AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03712280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: 550 mg tablet of rifaximin for oral administration
Study NCT02479750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ColdZyme® mouth spray
Study NCT02479750 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02739893 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scope Guide Assist
Description: Olympus has developed a new instrument which provides physicians a real-time, three dimensional visualization of position and configuration during colonoscopy. The Olympus ScopeGuide technology has received FDA clearance and can be used within the United States. The new technology called the 'scopeguide' has been developed that uses magnetic coils embedded into the scope to create a 3 D image of the shape of the entire scope inside the body that is projected onto the monitor to see. This acts as a GPS and shows the advancement of the scope through bends providing information on loops and thereby eliminating chances of loop formation, helping in loop reduction and also reducing the number of external maneuvers that may be required for the completion of colonoscopy.
Study NCT02739893 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard procedure for colonoscopy
Study NCT00171249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI571 400 mg
Description: STI571 capsules and tablets
Study NCT00171249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI571 600 mg
Description: STI571 capsules and tablets
Study NCT02172976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Study NCT02172976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT02172976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Study NCT02172976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT02172976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natriumfolinate
Study NCT04391478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone
Description: milrinone lactate, 1mg/ml, for intra venous use only
Study NCT04391478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 50mg sildenafil citrate/tablet, crushed in water taken by nasogastric tube
Study NCT04206865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan
Description: Patient's will be randomized to ICU initiation of sacubitril-valsartan vs. alternate oral vasodilator therapy in 1:1 fashion
Study NCT04206865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Oral Vasodilators
Description: Patient's will be randomized to ICU initiation of sacubitril-valsartan vs. alternate oral vasodilator therapy in 1:1 fashion. Alternate vasodilators will include ARBs, hydralazine and isosorbide dinitrate, and ACEi
Study NCT04554472 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Intraoperative ultrasound
Description: During the surgery, the standard AP and lateral x-rays will be performed. Additional projections (lateral 30 degrees tilt, and dorsal tangential view) will also be registered. Finally an intraoperative ultrasound of the wrist extensor tendons will be taken, checking the compartments individually in order to detect invasion of the dorsal cortex by the screws. In case of no protrusion, the patient will be registered as a correct fixation. Otherwise, it will be specified which position of the plate and which compartment the screw/s protrude. A screw with a correct measurement will then be replaced and implanted and recorded as a measurement error.
Study NCT01880606 — intervention group
Intervention type: PROCEDURE
Intervention: colonoscopy with endomicroscopy
Description: Examination will be performed in two steps. On the way from rectum to caecum, mucosa will be evaluated with white light endoscopy and random biopsies will be taken according to the routine standard with minimum of 2 biopsies from each 10 cm of colon. On the way back (from caecum to rectum) mucosa will be stained with indigo carmine and after intravenous fluorescein injection all macroscopically abnormal lesions will be examined by endomicroscopy and biopsied. Additionally, all places where random biopsies were taken will be also examined with endomicrosopy.
Study NCT02069795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Voice recording
Study NCT05678361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep/Nap
Description: Participants sleep after a maximum of three sessions of exposure therapy.
Study NCT03177395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP100-01 (calmangafodipir)
Description: PP100-01
Study NCT03177395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Description: NAC
Study NCT04440852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEACCH
Description: The Treatment and Education of Autistic and Communication Handicapped Children
Study NCT04304625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic Acid / Sodium chloride
Description: After the routine prophylactic IV or IM injection of the uterotonic used in the hospital protocol's -either oxytocin or carbetocin - (as recommended by the 2014 guidelines for prevention and management of postpartum hemorrhage from the CNGOF), the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the patient within 3 minutes after birth, slowly (over 30-60 seconds), once the cord has been clamped
Study NCT04304625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid / Sodium chloride
Description: After the routine prophylactic IV or IM injection of the uterotonic used in the hospital protocol's -either oxytocin or carbetocin - (as recommended by the 2014 guidelines for prevention and management of postpartum hemorrhage from the CNGOF), the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the patient within 3 minutes after birth, slowly (over 30-60 seconds), once the cord has been clamped
Study NCT03439137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-6548
Description: Oral tablet
Study NCT03439137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Intravenous administration
Study NCT03439137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MT-6548-matching placebo
Description: Oral tablet
Study NCT02823405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X4P-001
Description: X4P-001 100 mg capsules, administered orally, continuous daily dosing
Study NCT02823405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 2 mg/kg, administered by IV infusion every 3 weeks
Study NCT02045875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulera
Description: Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older.
Study NCT02045875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulera
Description: Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older.
Study NCT03001375 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic high anterior resection splenic flexure mobilization
Study NCT03001375 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic high anterior resection without splenic flexure mobilization
Study NCT03798041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Debridement Within 24 Hours After Surgery
Description: Debrided within 24 hours after surgery
Study NCT02842801 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hip manipulation
Description: High-amplitude and low-velocity thrust mobilization
Study NCT00659659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-563
Description: 1.0 mg/kg IV: MEDI-563
Study NCT00659659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-563
Description: 100 mg, 200 mg SC
Study NCT00659659 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comp.
Description: Placebo SC
Study NCT00659659 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo as a single IV infusion (Certain number of subjects)
Study NCT06249659 — intervention group
Intervention type: PROCEDURE
Intervention: Extubation in operative room
Description: Extubation takes place in operative room
Study NCT06249659 — intervention group
Intervention type: PROCEDURE
Intervention: Extubation in post anesthesia care unit
Description: Extubation takes place in post anesthesia care unit
Study NCT00484822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemiparina Sodica
Description: 3.500 UI/día.
Study NCT00484822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Heparina Cálcica
Description: 10.000 UI/día.
Study NCT02824354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene (Selincro®) 18 mg tablet
Description: Evaluate the efficacy, tolerability and safety of nalmefene for reduction of alcohol consumption (reduction of the number of monthly heavy drinking days, and daily total alcohol consumption) in alcohol-dependent patients with alcoholic compensated cirrhosis.
Study NCT02824354 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Evaluate the efficacy, tolerability and safety of nalmefene for reduction of alcohol consumption (reduction of the number of monthly heavy drinking days, and daily total alcohol consumption) in alcohol-dependent patients with alcoholic compensated cirrhosis.
Study NCT01376232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: GSk1278863 100mg
Study NCT01376232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863 + food
Description: High Fat meal + 100 mg GSK1278863
Study NCT01376232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Description: 600 mg Gemfibrozil
Study NCT00287690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genistein
Description: Drink taken once daily
Study NCT00287690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drink taken once daily
Study NCT01549938 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 20,000 IU cholecalciferol capsule, given once weekly for 16 weeks.
Study NCT01549938 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcellulose capsule identical in appearance to treatment
Study NCT02713087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: Infusion of Ephedrine 2mg/ml until MAP above 60 mmHg or until MAP has raised 20%
Study NCT02713087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Infusion of Phenylephrine 0,1mg/ml until MAP above 60 mmHg or until MAP has raised 20%
Study NCT02996474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Every effort should be made to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
Study NCT02996474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Will be administered at a dose of 20 mg/m\^2 by continuous intravenous infusion over 1 hour repeated daily ordinarily on days 8 through 12 and 15 through 19 of alternative cycles (ie: cycles 1, 3, 5, 7). Decitabine should be repeated every 6 weeks.
Study NCT00254631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone hydrochloride
Study NCT02297321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Describe patch
Description: Application of Describe patch over tattoo for approximately 5 minutes during Q-switched laser treatment
Study NCT02597647 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAIV
Description: Subjects underwent nasal swabs, nasopharyngeal saline wash, and nasal brushings pre, and 1-2 weeks and 4-6 weeks following intranasal administration of LAIV.
Study NCT02597647 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Subjects underwent nasal swabs, nasopharyngeal saline wash, and nasal brushings pre, and 1-2 weeks and 4-6 weeks following intranasal administration of saline nasal spray.
Study NCT04291222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iron biocorrodable coronary scaffold system
Description: Implantation of Iron biocorrodable coronary scaffold system
Study NCT00672334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate
Description: In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium bicarbonate at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
Study NCT00672334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium chloride at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
Study NCT02437461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone hexacetonide
Description: intraarticular knee injection
Study NCT02437461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone hexacetonide
Description: intraarticular knee injection
Study NCT00948649 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take placebo pills for 21-days using the same regimen as the varenicline study period.
Study NCT00948649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Day 1 - Day 3 0.5mg once daily Day 4 - Day 7 0.5mg twice daily Day 8 - End of Treatment 1.0mg twice daily
Study NCT00258557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LPV/RTV
Description: 400/100 mg twice daily or 800/200 mg daily depending on the country for max. 192 weeks
Study NCT00258557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC-114/RTV
Description: two 400 mg tablets of TMC114 + one 100 mg capsule of RTV daily for max. 192 weeks
Study NCT03439137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa-matching placebo
Description: Intravenous administration
Study NCT04041817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trigger setting of pressure support ventilation
Description: Trigger variations will be performed following increasing steps of 3 L/min every 15 minutes, from 0.2 to 15 L/min (0.2 - 3 - 6 - 9 - 12 - 15).
Study NCT02924935 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Histidine
Description: L-Histidine in 500mg capsules taken at a dose of 50mg/kg to maintain high-normal serum histidine levels
Study NCT02385786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: Eight week course in mindfulness meditation training with elements of cognitive behavioral therapy
Study NCT04236843 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Feces
Description: Feces from healthy donor
Study NCT01860859 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Closure of the hysterotomy at the time of primary cesarean
Study NCT02581592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208
Description: A single inhaled dose of TD 4208 (175 mcg)
Study NCT02891473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mézières Method
Description: 10 sessions of rehabilitative treatment according to the Mézières Method, 2 sessions per week for 5 weeks, each lasting 1 hour.
Study NCT02891473 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home based exercise program
Description: 1 single training session lasting 1 hour for the explication of the rehabilitation program that the patient has to perform independently at home followed by 2 sessions of home based exercises per week for 5 weeks, each lasting 1 hour.
Study NCT02858401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Tablet(s) administered orally once every 2 weeks
Study NCT02858401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet(s) administered orally once every 2 weeks
Study NCT02858401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ARV regimen
Description: Participants' current ARV regimen must be used in accordance with their prescribing information and may include the following: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), raltegravir, dolutegravir, rilpivirine, and maraviroc.
Study NCT02858401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV regimen
Description: Participants' current ARV regimen must be used in accordance with their prescribing information and may include the following: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), raltegravir, dolutegravir, rilpivirine, and maraviroc.
Study NCT04700969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: : A support program to facilitate implementation of evidence-based practice for postoperative urinary retention
Description: A 12-month implementation support program for multi-professional internal facilitator teams
Study NCT02617615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-110
Description: MB-110 is a novel, potent, and selective HCV inhibitor against the NS5A protein. In the preclinical studies, MB-110 demonstrated picomolar EC50s towards various genotypes and favorable pharmacokinetic properties to support the once daily dosing regimen.
Study NCT02617615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It will be identical in appearance and similar in weight to the MB-110 hard-gel capsule.
Study NCT01305811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Sterile insertive needles are applied by licensed, experienced practitioners.
Study NCT01305811 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Sterile insertive needles are applied by licensed, experienced practitioners.
Study NCT03511703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib, a small molecule anti-angiogenic targeted drug that has been demonstrated to be safe and effective after failure of standard chemotherapy for advanced gastric cancer, has been initially successful in phase II clinical trials for the treatment of unresectable advanced HCC patients. The efficacy of ralfiny in the treatment of Oriental population (ORIENTAL study) is better. The randomized, doubleblind, multi-center phase III clinical study of apatinib second-line treatment of advanced hepatocellular carcinoma showed a good efficacy and safety. Currently, Phase III clinical studies of apatinib in HCC patients undergoing systemic chemotherapy or sorafenib treatment have progressed. Initial results lso showed good efficacy and safety.
Study NCT03511703 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy drugs+Iodized oil
Description: Intra-arterial infusion chemotherapy for tumors, commonly used chemotherapy drugs include anthracyclines, platinum, etc.; chemotherapeutic drugs and embolic agents are mixed together and injected through the blood supply artery of the tumor. The most commonly used embolic agent for TACE treatment is a lipiodol emulsion. First infusion of some chemotherapy drugs, the general infusion time should not be \<20 min. Then another part of the chemotherapeutic drugs and lipiodol were mixed into emulsions for embolization. The amount of lipiodol is generally 5-20 ml, not more than 30 ml.
Study NCT04112732 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin
Description: Multivitamin
Study NCT04112732 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00889239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lithia-disilicate-based crown
Description: all-ceramic crown
Study NCT03768713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: Insomnia subjects will take a nightly pill of 20 mg Suvorexant for eight weeks.
Study NCT03768713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Insomnia subjects will take a nightly pill of 20 mg placebo for eight weeks.
Study NCT00447083 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: UVB
Description: UVB exposure by a tanning bed